Video
Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL
Author(s):
In Partnership With:
James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia.
James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia (ALL).
CD19 is an ideal target in B-cell ALL, says McCloskey, as it is expressed on the surface of the cells of these patients.
The antibody-drug conjugate loncastuximab tesirine (ADCT-402), which is designed to target CD19, is currently being evaluated in patients with relapsed or refractory B-cell ALL.
